Insilico Medicine has initiated a Phase III clinical trial evaluating Rentosertib (formerly ISM001-055/INS018_055), an orally administered small-molecule TNIK inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF).

• Trial Design: The randomised, double-blind, placebo-controlled Phase III study will enrol approximately 320 patients across China to evaluate the efficacy and safety of once-daily Rentosertib over a 52-week treatment period.
• AI-Driven Discovery: Rentosertib was discovered using Insilico Medicine’s proprietary generative AI platform, combining AI-based target identification with AI-assisted small-molecule design.
• Primary Endpoint: The study will assess the annual rate of decline in Forced Vital Capacity (FVC), a key measure of lung function, with additional endpoints evaluating disease progression.

This summary is based on a press release issued by Insilico Medicine.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.